Announcements Trials
Browse Landscape

Phase

Phase 1 2Phase 1/2 1

Status

Recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other solid neoplasm 1Other hematologic neoplasm 1Lymphoid 1Genitourinary 1

Conditions

Solid Tumor 1

Interventions

pembrolizumab 41Injections 39toripalimab 23Nivolumab 22Cisplatin 19Pemetrexed 18Carboplatin 18Cyclophosphamide 17Paclitaxel 14Bevacizumab 14fludarabine 12Gemcitabine 11tislelizumab 10Ipilimumab 10spartalizumab 9Irinotecan 9atezolizumab 8Docetaxel 8Oxaliplatin 7Leucovorin 7Fluorouracil 7Capecitabine 6sintilimab 5Interleukin-2 5Albumin-Bound Paclitaxel 5130-nm albumin-bound paclitaxel 5trifluridine tipiracil drug combination 4sotorasib 4pazopanib 4palbociclib 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1/2 × WW Domain-Containing Oxidoreductase × Other solid neoplasm × Clear all
NCT07229638 2026-03-20

A IB/II Phase Clinical Study on the Safety, Tolerability, and Efficacy of SHR-9839(sc) in Combination Anti-tumor Therapy in Patients With Solid Tumors

Suzhou Suncadia Biopharmaceuticals Co., Ltd.

Phase 1/2 Recruiting
70 enrolled
Other solid neoplasm

Solid Tumor

Data powered by HemOnc (CC BY 4.0) Colophon âš¡